The International Journal of Biochemistry & Cell Biology
β-Thalassaemia: emergence of new and improved iron chelators for treatment
Section snippets
General introduction and overview: β-thalassaemia results in iron overload
β-Thalassaemia is an inherited disorder of haemoglobin synthesis that was first documented by Drs. Thomas Cooley and Pearl Lee in 1925 (Weatherall, 1981; Olivieri & Brittenham, 1997). The disease is common in Mediterranean countries, the Middle East, the Indian subcontinent, South East Asia, Asian parts of Russia, and the northern-third of China (Weatherall, 1981; Olivieri & Brittenham, 1997). The ineffective erythropoiesis in β-thalassaemia is due to defective haemoglobin synthesis, leading to
Pathogenesis of β-thalassaemia
Patients with β-thalassaemia have a reduction or a lack of synthesis of the β-chain of haemoglobin while the α-chain synthesis remains unimpaired (Weatherall, 1981; Hoffbrand, Pettit, & Moss, 2001). The imbalance between α- and β-chain causes the α-chain to form unstable aggregates that precipitate and affect erythrocyte membrane plasticity (Hoffbrand et al., 2001). This leads to erythrocyte destruction in the bone marrow and spleen, resulting in ineffective erythropoiesis and anaemia (
Desferrioxamine
Iron overload diseases can be readily treated using chelation therapy. An ideal iron chelator should be orally effective, highly efficient, economical, specific for iron and show low toxicity. Currently, patients are treated with DFO (Fig. 2) which is the only widely used and approved iron chelator (Richardson, 1999). However, DFO has poor absorption capability across the gastrointestinal tract, rendering it orally ineffective (Richardson, 1999, Franchini et al., 2000). Apart from the
Conclusions
There has been no suitable replacement for DFO over the last few decades for the treatment of β-thalassaemia. However, chelating agents with better oral activity and efficacy have been designed and are undergoing development. These ligands may be used as alternatives to DFO or as agents that can be used alone or in combination to induce maximum iron excretion. Finally, in the future, the individual tailoring of chelation therapy to maximise iron excretion will benefit from having the choice of
Acknowledgements
Children’s Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children’s Hospital. This project was supported by a fellowship and project grant from the National Health and Medical Research Council of Australia and a commercial grant from Metabolic Pharmaceuticals Ltd., Melbourne. The authors thank Ms. Juliana Kwok of the Iron Metabolism and Chelation Program for her comments on the manuscript prior to submission.
References (20)
- et al.
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
Lancet
(2002) - et al.
Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
Journal of Laboratory and Clinical Medicine
(1999) - et al.
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning
Blood
(2002) - et al.
3-Hydroxy-(4H)-benzopyran-4-ones as potential iron chelating agents in vivo
Bioorganic and Medicinal Chemistry
(2001) - et al.
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
Blood
(2000) - et al.
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture
Blood
(2001) - et al.
Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture
Journal of Laboratory and Clinical Medicine
(2001) - et al.
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial
Blood Cells, Molecules, and Diseases
(2002) - et al.
Iron chelating therapy and the treatment of thalassemia
Blood
(1997) - et al.
Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron-chelating agents for the treatment of iron overload disease
Journal of Laboratory and Clinical Medicine
(1998)
Cited by (32)
Manipulating redox active metal metabolism to enhance cancer therapy
2019, Improving the Therapeutic Ratio in Head and Neck CancerRedox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics
2016, Biochimica et Biophysica Acta - Molecular Cell ResearchCitation Excerpt :Just as folate is an essential nutrient for DNA synthesis, iron is also crucial for DNA synthesis and both of these nutrients are required in higher amounts by tumor cells, making each appropriate therapeutic targets [2,237,238]. For many decades, chelators have been used to treat conditions of iron or copper overload, such as in β-thalassemia or Wilson's disease, respectively [242,243]. However, it is only more recently that their roles in other diseases, such as neurodegeneration and cancer, have been considered [2,239,244].
The interaction of phenolic acids with Fe(III) in the presence of citrate as studied by isothermal titration calorimetry
2014, Food ChemistryCitation Excerpt :Therefore, it is important to keep the balance between iron import and export to maintain the iron homeostasis. Some iron chelators such as Desferal® or ICL670A can be used in medicine to protect patients from the consequences of iron overload and iron toxicity in organs and tissues (Aouad et al., 2002; Faa & Crisponi, 1999; Liu & Hider, 2002; Wong & Richardson, 2003). Additionally, some polyphenols also have the potential to be used as chelators to modulate physiological reactions involving iron and other transition metals (Blache, Durand, Prost, & Loreau, 2002; Elhabiri, Carrer, Marmolle, & Traboulsi, 2006; Haslam, 1996).
Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition
2014, Biochimica et Biophysica Acta - Reviews on CancerCitation Excerpt :The excessive production of hydroxyl radicals can stimulate apoptosis via DNA oxidation, mitochondrial damage, and/or the peroxidation of membrane lipids [35]. Oxidative reactions such as these ultimately lead to the tissue and organ damage present in diseases leading to cellular iron loading (e.g., hereditary hemochromatosis, β-thalassemia and Friedreich's ataxia [13,36–38]). Oxidative DNA lesions caused by ROS can result in DNA modifications through single or double strand breaks or even in the modification of nucleotide bases [39].
Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by Salvia miltiorrhiza
2013, Journal of EthnopharmacologyCitation Excerpt :Hepatic fibrosis is a major cause of morbidity and mortality in patients with secondary iron overload disease and also frequently occurs in patients with primary hemochromatosis (Ikuta et al., 2004). Although iron chelators, such as DFO and DFP, are widely accepted treatments for removing excessive iron, the toxic side effects and cumbersome administration schedule encourage the need for more safe and convenient therapeutic options (Wong and Richardson, 2003; Acton et al., 2008). SM belongs to the family of Labiatae and is highly valued for its dried roots in Chinese medicine (Lam et al., 2008).
Enzymatic synthesis of catechol and hydroxyl-carboxic acid functionalized chitosan microspheres for iron overload therapy
2011, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :The generated reactive oxygen species oxidize biomolecules (lipids, proteins, and nucleic acids) thereby damaging cells, tissues, and organs alike. Consequently, iron overload has been attributed to diseases such as β-thalassemia, neurodegenrative diseases, cancer, and arteriosclerosis [1,9–11]. To treat or protect patients from the consequences of iron toxicity, iron-chelating drugs have been introduced in clinical practice.